Hannant D, Jessett D M, O'Neill T, Dolby C A, Cook R F, Mumford J A
Department of Infectious Diseases, Animal Health Trust, Newmarket, Suffolk.
Res Vet Sci. 1993 May;54(3):299-305. doi: 10.1016/0034-5288(93)90126-z.
An experimental (ISCOM) vaccine previously shown to protect hamsters from lethal challenge with equid herpesvirus-1 (EHV-1), was tested in horses. Vaccination with EHV-1 ISCOMs induced serum antibodies to the major virus glycoproteins gp10, 13, 14, 17, 18 and 21/22a, whereas antibody responses to gp2 were weak or absent. High levels of virus neutralising antibody of long duration were induced, but did not prevent challenge infection with virus of the homologous strain. However, in the vaccinated ponies there was a significant reduction in clinical signs, nasal virus excretion and cell associated viraemia compared with age-matched unvaccinated controls. There was a strong correlation between pre-challenge levels of serum virus neutralising antibody and the duration and total amount of virus excreted from the nasopharynx.
一种先前已证明能保护仓鼠免受马疱疹病毒1型(EHV-1)致死性攻击的实验性(免疫刺激复合物,ISCOM)疫苗在马匹身上进行了测试。用EHV-1 ISCOM疫苗接种可诱导产生针对主要病毒糖蛋白gp10、13、14、17、18和21/22a的血清抗体,而对gp2的抗体反应较弱或不存在。诱导产生了高水平的、持续时间长的病毒中和抗体,但不能预防同源毒株病毒的攻击感染。然而,与年龄匹配的未接种疫苗的对照相比,接种疫苗的小马的临床症状、鼻腔病毒排泄和细胞相关病毒血症显著减少。攻击前血清病毒中和抗体水平与从鼻咽部排出的病毒持续时间和总量之间存在很强的相关性。